Loading...
Sumitomo Pharma Co., Ltd.
SMDPY•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$7.77
$0.00(0.00%)
Sumitomo Pharma Co., Ltd. (SMDPY) Financial Performance & Income Statement Overview
Review Sumitomo Pharma Co., Ltd.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
26.79%
↑ 26.79%
Operating Income Growth
104.21%
↑ 104.21%
Net Income Growth
107.50%
↑ 107.50%
Operating Cash Flow Growth
106.82%
↑ 106.82%
Operating Margin
7.22%
↑ 7.22%
Gross Margin
61.53%
↑ 61.53%
Net Profit Margin
5.93%
↑ 5.93%
ROE
15.48%
↑ 15.48%
ROIC
5.73%
↑ 5.73%
Sumitomo Pharma Co., Ltd. (SMDPY) Income Statement & Financial Overview
Review Sumitomo Pharma Co., Ltd.'s (SMDPY) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $105.65B | $112.43B | $90.07B | $90.67B |
| Cost of Revenue | $39.67B | $41.44B | $37.38B | $34.95B |
| Gross Profit | $65.98B | $71.00B | $52.70B | $55.73B |
| Gross Profit Ratio | $0.62 | $0.63 | $0.59 | $0.61 |
| R&D Expenses | $13.13B | $10.47B | $13.15B | $13.12B |
| SG&A Expenses | $49.56B | $41.04B | $44.64B | $45.36B |
| Operating Expenses | $62.69B | $49.59B | $57.79B | $58.83B |
| Total Costs & Expenses | $102.36B | $91.03B | $95.16B | $93.78B |
| Interest Income | $0.00 | $15.64B | $0.00 | $22.33B |
| Interest Expense | $7.45B | $0.00 | $23.41B | $2.02B |
| Depreciation & Amortization | $5.81B | $6.07B | $6.78B | $6.91B |
| EBITDA | $22.29B | $27.47B | -$19.42B | $26.14B |
| EBITDA Ratio | $0.21 | $0.24 | -$0.22 | $0.29 |
| Operating Income | $3.29B | $21.41B | -$5.09B | -$3.10B |
| Operating Income Ratio | $0.03 | $0.19 | -$0.06 | -$0.03 |
| Other Income/Expenses (Net) | -$9.70B | $35.03B | -$44.52B | $20.31B |
| Income Before Tax | -$6.42B | $56.43B | -$49.61B | $17.20B |
| Income Before Tax Ratio | -$0.06 | $0.50 | -$0.55 | $0.19 |
| Income Tax Expense | -$8.83B | $2.98B | -$1.45B | $1.27B |
| Net Income | $2.42B | $53.45B | -$48.17B | $15.94B |
| Net Income Ratio | $0.02 | $0.48 | -$0.53 | $0.18 |
| EPS | $6.08 | $134.53 | -$121.24 | $40.11 |
| Diluted EPS | $6.08 | $134.53 | -$121.24 | $40.11 |
| Weighted Avg Shares Outstanding | $397.29M | $397.29M | $397.29M | $397.29M |
| Weighted Avg Shares Outstanding (Diluted) | $397.29M | $397.29M | $397.29M | $397.29M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan